WallStSmart

BioNTech SE (BNTX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BioNTech SE generates 377959% more annual revenue ($2.81B vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -44.6%. BNTX earns a higher WallStSmart Score of 35/100 (F).

BNTX

Avoid

35

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 7.7Quality: 8.5
Piotroski: 3/9Altman Z: 6.11

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BNTXUndervalued (+28.6%)

Margin of Safety

+28.6%

Fair Value

$153.17

Current Price

$88.08

$65.09 discount

UndervaluedFair: $153.17Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNTX4 strengths · Avg: 10.0/10
PEG RatioValuation
0.0510/10

Growing faster than its price suggests

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.1110/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BNTX4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-6.7%2/10

ROE of -6.7% — below average capital efficiency

Revenue GrowthGrowth
-35.4%2/10

Revenue declined 35.4%

EPS GrowthGrowth
-43.2%2/10

Earnings declined 43.2%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BNTX

The strongest argument for BNTX centers on PEG Ratio, Price/Book, Debt/Equity. PEG of 0.05 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BNTX

The primary concerns for BNTX are Piotroski F-Score, Return on Equity, Revenue Growth.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BNTX profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BNTX is growing revenue faster at -35.4% — sustainability is the question.

RVMD generates stronger free cash flow (-356M), providing more financial flexibility.

Bottom Line

BNTX scores higher overall (35/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioNTech SE

HEALTHCARE · BIOTECHNOLOGY · USA

BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?